The global competent cells market size is valued at USD 1.88 billion in 2022. This value is estimated to grow at a CAGR of 10.40% and reach USD 3.08 billion by 2027. The global competent cells market is developing at a rapid pace.
The cells which can proliferate are made competent to get faster results. The US FDA has approved new guidelines for testing retroviral vector-based human gene therapy for a replication-competent retrovirus, which will boost the research in the field of the competent cell as there is a more important requirement of retrovirus therapy and vaccine. The competent cell technique can be used to create a vaccine for retrovirus. The synthetic biology company SGI-DNA and Gibson Assembly Reagents have launched Vmax X2 competent cells. It is designed to generate two to four times more soluble protein in half of the current reliance on E. coli.
COVID-19 impact on the global competent cells market:
In this time of COVID – 19 pandemic, the competent cell technique can be used in the research as a bacterial artificial chromosome used to study the stature of coronavirus. It could boost the market growth of the competent cell market. The countries in the Asia Pacific, such as India and China, are investing more in the research of competent cell technology.
MARKET DRIVERS:
The global competent cells market is driven by the increasing demand for recombinant DNA technique products.
There are many applications of recombinant DND techniques such as in gene therapy, vaccine production, cancer treatment, and treatment of retrovirus. The advancement in molecular engineering and growing research in therapeutic products used to treat several diseases are likely to bolster the market demand.
Growing demand for recombinant proteins and molecular replicated products, progress in molecular cloning technology with the advent of innovations, and numerous government policies and support for life science research are the main factors propelling the competent cells market development during the forecast period. The industry is further expected to be driven by the advances in successful research and development on pharmaceutical drugs for treating various diseases, increased government spending on research programmers, and a favorable reimbursement and regulatory environment. As the number of diseases grows, governments in most countries have increased their attention on upgrading healthcare facilities and discovering therapies for specific diseases. As a result, they've expanded their investment in biotechnology firms and simplified regulations to encourage the discovery of therapies for serious diseases.
In the near future, increased investment for DNA cloning technologies studies in academic research centers and using these products in therapeutics is expected to boost the market growth. Increased government and industry investments and the launch of novel product categories are expected to fuel demand growth.
MARKET RESTRAINTS:
The high cost of research and the advanced infrastructure required for the competent cell technique is restraining the growth of the competent cells market. These techniques require a skilled professional, which is also slowing down the growth of the global competent cells market. Due to the need for the cells to stay cold, the process of creating competent cells is challenging. Because the cells are so sensitive and fragile while being made competent, this is essential. Keeping the temperature low throughout processing helps to avoid cell death.
REPORT COVERAGE:
|
REPORT METRIC |
DETAILS |
|
Market Size Available |
2022 to 2027 |
|
Base Year |
2021 |
|
Forecast Period |
2022 to 2027 |
|
Segments Analysed |
By Type, Application, End-User, and Region |
|
Various Analyses Covered |
Global, Regional & Country Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities |
|
Regions Analysed |
North America, Europe, Asia Pacific, Latin America, Middle East, and Africa |
This market research report on the global competent cells market has been segmented and sub-segmented based on the type, application, and end-user.
Competent Cells Market – By Type:
Based on type, chemically competent cells are projected to account for the largest share of the global competent cells market. However, during the forecast period, the electrocompetent cells segment is predicted to rise at the fastest CAGR.
Competent Cells Market – By Application:
Based on the application, the cloning segment dominates the competent cells market. Bacterial transformation is used in DNA cloning, in which the bacteria take up the genetic material. This method is commonly used in molecular biology applications. This sector has grown as a result of the government's increasing support and investments.
Competent Cells Market – By End User:
Based on End-User, due to increased research spending in biotechnological applications, the academic research institutes segment is expected to account for the largest share of the market. During the forecast period, the pharmaceutical and biotechnology companies segment is expected to expand the most. The rising investments in research for developing genomics and proteomics-based products are driving this segment's growth.
Competent Cells Market – By Region:
North America is estimated to constitute the largest share in the global competent cells market. At the same time, the Asia Pacific region is expected to witness the fastest growth and overtake North America, being the second-largest shareholder for the market during the forecast period. The Asia-Pacific competent cells market is expected to account for most of the global competent cells market during the forecast period. Extensive studies on DNA cloning technology in the field and the existence of key market players are credited with the development. Because of the developing healthcare and research infrastructure, especially in the region's emerging countries, the Asia-Pacific region is expected to expand significantly.
KEY MARKET PARTICIPANTS:
Some of the prominent companies operating in the global competent cells market profiled in this report are BioDynamics Laboratory, Inc. (Japan), GCC Biotech (India), SMOBIO Technology (Taiwan), Thermo Fisher Scientific, Inc. (the U.S), QIAGEN N.V. (Germany), OriGene Technologies (U.S.), Merck KGaA (Germany), Promega Corporation (U.S.), Bioline (U.K.) and Zymo Research (U.S.).
Recent Market Developments:
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Type
5.1.1 Chemically
5.1.2 Electrocompetent
5.1.3 Y-o-Y Growth Analysis, By Type
5.1.4 Market Attractiveness Analysis, By Type
5.1.5 Market Share Analysis, ByType
5.2 Application
5.2.1 Cloning
5.2.1.1 Subcloning & Routine Cloning
5.2.1.2 Phage Display Library Construction
5.2.1.3 Toxic/Unstable Dna Cloning
5.2.1.4 High-Throughput Cloning
5.2.2 Protein Expression
5.2.3 Other Applications
5.2.3.1 Mutagenesis
5.2.3.2 Large Plasmid Transformation
5.2.3.4 Single-Stranded Dna Production
5.2.3.5 Lentiviral Vector Production
5.2.7 Y-o-Y Growth Analysis, By Application
5.2.8 Market Attractiveness Analysis, By Application
5.2.9 Market Share Analysis, By Application
5.3 End User
5.3.1 Pharmaceutical Companies
5.3.2 Academia
5.3.3 Y-o-Y Growth Analysis, By EndUser
5.3.4 Market Attractiveness Analysis, By EndUser
5.3.5 Market Share Analysis, By EndUser
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Type
6.1.3.3 By Application
6.1.3.4 By EndUser
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Type
6.1.4.3 By Application
6.1.4.4 By EndUser
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Type
6.1.5.3 By Application
6.1.5.4 By EndUser
6.2 North America
6.2.1 Introduction
6.2.2 United States
6.2.3 Canada
6.3 Europe
6.3.1 Introduction
6.3.2 U.K
6.3.3 Spain
6.3.4 Germany
6.3.5 Italy
6.3.6 France
6.4 Asia-Pacific
6.4.1 Introduction
6.4.2 China
6.4.3 India
6.4.4 Japan
6.4.5 Australia
6.4.6 South Korea
6.5 Latin America
6.5.1 Introduction
6.5.2 Brazil
6.5.3 Argentina
6.5.4 Mexico
6.5.5 Rest of Latin America
6.6 Middle East & Africa
6.6.1 Introduction
6.6.2 Middle-East
6.6.3 Africa
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 BioDynamics Laboratory, Inc. (Japan)
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 GCC Biotech (India)
8.3 SMOBIO Technology (Taiwan)
8.4 Thermo Fisher Scientific, Inc. (U.S)
8.5 QIAGEN N.V. (Germany)
8.6 OriGene Technologies (U.S.)
8.7 Merck KGaA (Germany)
8.8 Promega Corporation (U.S.)
8.9 Bioline (U.K.)
8.10 Zymo Research (U.S.)
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Talk to our analyst and get customised report done according to your research needs
Check if you can avail any discount. Submit your details and our team will get back to you.
Request to avail a free sample report that reflects this market and its growth.
